Dendritic cell immune modulation in cancer patients
A Lola and John Grace Distinguished Lecture in Cancer Research
Professor Jolanda de Vries is Chair of the Department of Medical Biosciences and President of the Dutch Society of Immunology (DSI/NVVI). She was one of the pioneers to translate dendritic cell (DC) biology into potential clinical applications. The first clinical phase I/II studies in which patients were vaccinated with DCs loaded with tumour-specific peptides were initiated in 1997. She also developed a novel immuno-monitoring assay that is highly predictive for extended survival after vaccination with DCs. Her primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC.
Jolanda de Vries did her PhD at the Department of Dermatology of University Medical Centre Utrecht from 1991-1997. In 1997, she joined the Department of Tumor Immunology, Radboud University Nijmegen Medical Centre/Nijmegen Centre for Molecular Life Sciences. By the end of that year, she was able to provide the first DC-based vaccine for a melanoma patient, the first patient receiving DCs in the Netherlands, with a close collaboration with the Departments of Medical Oncology and Hematology. Over the last 8 years, a clinical vaccination program in which tumor-associated antigens loaded on DCs to treat melanoma patients, has been established. Primary scientific interest continues along the lines of DC-immunotherapy and in particular the migration and imaging of DC.
Professor Jolanda de Vries is Chair of the Department of Medical Biosciences and President of the Dutch Society of Immunology (DSI/NVVI). She was one of the pioneers to translate dendritic cell (DC) biology into potential clinical applications. The first clinical phase I/II studies in which patients were vaccinated with DCs loaded with tumour-specific peptides were initiated in 1997. She also developed a novel immuno-monitoring assay that is highly predictive for extended survival after vaccination with DCs. Her primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC.
Jolanda de Vries did her PhD at the Department of Dermatology of University Medical Centre Utrecht from 1991-1997. In 1997, she joined the Department of Tumor Immunology, Radboud University Nijmegen Medical Centre/Nijmegen Centre for Molecular Life Sciences. By the end of that year, she was able to provide the first DC-based vaccine for a melanoma patient, the first patient receiving DCs in the Netherlands, with a close collaboration with the Departments of Medical Oncology and Hematology. Over the last 8 years, a clinical vaccination program in which tumor-associated antigens loaded on DCs to treat melanoma patients, has been established. Primary scientific interest continues along the lines of DC-immunotherapy and in particular the migration and imaging of DC.
Practical information
- Informed public
- Free
- This event is internal
Organizer
- Prof. Elisa Oricchio
Contact
- Lisa Smith, ISREC Administrative Assistant